Recombinant Rv0222 protein from Mycobacterium tuberculosis regulates host Th9 differentiation function in vitro

Area of Science:

• Immunology
• Microbiology
• Genetics

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a growing global health concern.
• Genomic analysis reveals differences between Mtb and BCG strains, with Rv0222 located in the Mtb RD4 region.
• Understanding Mtb's immune evasion strategies is crucial for developing effective TB interventions.

Purpose of the Study:

• To investigate the immunomodulatory effects of the Mtb Rv0222 protein.
• To determine the impact of recombinant Rv0222 (rRv0222) on host immune cells, specifically Th9 responses.
• To evaluate Rv0222 as a potential vaccine candidate or therapeutic target for TB.

Main Methods:

• Construction and expression of recombinant Rv0222 (rRv0222) using the pET32a vector.
• Assessment of spleen cell proliferation using the CCK8 assay.
• Quantification of Th9-related cytokines (IL-4, IL-9, IL-10, TGF-β1) via ELISA.
• Measurement of IL-9 and TGF-β1 mRNA expression using RT-qPCR.
• Analysis of T cell populations (CD3+CD4+, CD4+IL-4+, CD4+IL-9+) by flow cytometry.

Main Results:

• rRv0222 stimulation decreased spleen cell proliferation in a dose-dependent manner.
• Increased levels of Th9-related cytokines (IL-4, IL-9, IL-10, TGF-β1) and their mRNA expression were observed.
• Flow cytometry revealed a decreased proportion of CD3+CD4+ T cells but increased proportions of CD4+IL-4+ and CD4+IL-9+ T cells.

Conclusions:

• Recombinant Rv0222 up-regulates Th9 cell-related factors and inhibits host cell proliferation.
• Rv0222 plays a role in regulating host immune responses during Mtb infection.
• Rv0222 shows promise as a potential vaccine candidate and therapeutic target for tuberculosis.